Placebo effects in trials evaluating 12 selected minimally invasive interventions: a systematic review and meta-analysis
| Autor: | Ole Tjomsland, Jens Ivar Brox, Robin Holtedahl |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Research design
medicine.medical_specialty Evidence-based practice MEDLINE Cochrane Library Placebo Neurosurgical Procedures Internal medicine medicine Humans Minimally Invasive Surgical Procedures Cardiac Surgical Procedures Adverse effect business.industry Research General Medicine Placebo Effect Surgery Systematic review Treatment Outcome Evidence Based Practice Research Design Meta-analysis business |
| Zdroj: | BMJ Open |
| ISSN: | 2044-6055 |
| Popis: | Objectives To analyse the impact of placebo effects on outcome in trials of selected minimally invasive procedures and to assess reported adverse events in both trial arms. Design A systematic review and meta-analysis. Data sources and study selection We searched MEDLINE and Cochrane library to identify systematic reviews of musculoskeletal, neurological and cardiac conditions published between January 2009 and January 2014 comparing selected minimally invasive with placebo (sham) procedures. We searched MEDLINE for additional randomised controlled trials published between January 2000 and January 2014. Data synthesis Effect sizes (ES) in the active and placebo arms in the trials’ primary and pooled secondary end points were calculated. Linear regression was used to analyse the association between end points in the active and sham groups. Reported adverse events in both trial arms were registered. Results We included 21 trials involving 2519 adult participants. For primary end points, there was a large clinical effect (ES≥0.8) after active treatment in 12 trials and after sham procedures in 11 trials. For secondary end points, 7 and 5 trials showed a large clinical effect. Three trials showed a moderate difference in ES between active treatment and sham on primary end points (ES ≥0.5) but no trials reported a large difference. No trials showed large or moderate differences in ES on pooled secondary end points. Regression analysis of end points in active treatment and sham arms estimated an R 2 of 0.78 for primary and 0.84 for secondary end points. Adverse events after sham were in most cases minor and of short duration. Conclusions The generally small differences in ES between active treatment and sham suggest that non-specific mechanisms, including placebo, are major predictors of the observed effects. Adverse events related to sham procedures were mainly minor and short-lived. Ethical arguments frequently raised against sham-controlled trials were generally not substantiated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|